Silverarc Capital Management’s Mereo BioPharma MREO Stock Holding History

Silverarc Capital Management’s Portfolio MREO Stock Details MREO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-156,195	Closed	-$175K	–	87
2022 Q2	$175K	Sell	156,195 -79,320	-34%	-$61.5K	0.05%	66
2022 Q1	$264	Buy	235,515 +2,332	+1%	+$3.02K	0.11%	60
2021 Q4	$373K	Sell	233,183 -132,478	-36%	-$265K	0.15%	67
2021 Q3	$885K	Sell	365,661 -40,210	-10%	-$106K	0.5%	59
2021 Q2	$1.29K	Buy	405,871 +230,871	+132%	+$775K	0.57%	62
2021 Q1	$590K	Sell	175,000 -105,000	-38%	-$371K	0.32%	67
2020 Q4	$1M	Buy	+280,000	New	+$701K	0.58%	50

Other funds holding MREO

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Silverarc Capital Management's MREO Position: Q3 2022 in Review

Silverarc Capital Management sold out of Mereo BioPharma (MREO) in Q3 2022, closing a stake of 156,195 shares — an estimated $175K sold.

Silverarc Capital Management first reported a position in MREO in Q4 2020 and held it in 7 quarters. The position peaked at $1M in Q4 2020. 63 funds tracked by Wall St. Rank hold MREO as of Q3 2022.

Silverarc Capital Management reported no remaining Mereo BioPharma position as of Q3 2022 after selling out during the quarter.
Silverarc Capital Management sold 156,195 Mereo BioPharma shares in Q3 2022, an estimated $175K.
Silverarc Capital Management first reported a position in Mereo BioPharma in Q4 2020 and held it in 7 quarters.
Silverarc Capital Management's Mereo BioPharma position peaked at $1M in Q4 2020.
63 funds tracked by Wall St. Rank held Mereo BioPharma as of Q3 2022.

Based on Silverarc Capital Management's 13F filing for Q3 2022, filed 28 Oct 2022.